The success of Sildenafil initially sparked a period of growth for pharma, but recent changes present a uncertain picture for investors. Off-patent versions are eating into profits, and continued legal battles add https://idaombb870144.blog2news.com/41699452/the-blue-pill-and-pharma-a-risky-investment